Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Build A Bear Workshop Inc (BBW) vs Cytokinetics Inc (CYTK) Price & Performance

Build A Bear Workshop IncTrade
Cytokinetics IncTrade

Price performance (Past 24H)

Key statistics

Build A Bear Workshop Inc vs Cytokinetics Inc — how do they compare? Build A Bear Workshop Inc trades at $36.88 (market cap $467.15M), while Cytokinetics Inc trades at $76.67 (market cap $10.78B). The key difference: Cytokinetics Inc is far larger — about 23.1× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.47% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.

BBWCYTK
Market Cap
$467.15M$10.78B
Sector
Consumer CyclicalTechnology
52-Week High
$75.85$87.26
52-Week Low
$29.84$33.23
Enterprise Value
$566.59M$10.88B
Dividend Yield
2.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Build A Bear Workshop Inc

Build-A-Bear Workshop (BBW) trades at $36.86, up 6.19% today, with a bullish technical signal and strong analyst support. The stock exhibits attractive valuation metrics, including a P/E of 8.73 and P/S of 0.92, alongside robust profitability with a 10.48% net income margin and 35.87% ROE. Recent earnings have consistently beaten estimates, and the company maintains a debt-free balance sheet while executing a growth strategy focused on international expansion and brand partnerships.

The outlook for BBW is positive, driven by earnings momentum and a consensus price target of $62.50 implying significant upside. Key risks include near-term consumer spending volatility and execution of expansion plans, but strong fundamentals and shareholder returns via dividends support a favorable risk-reward profile for long-term investors.

Cytokinetics Inc

Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.

The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.

Returns comparison

Trailing returns across standard periods

About Build A Bear Workshop Inc

Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.

Read more on BBW

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK